News

Type 2 diabetes disease progression and successful intervention depend on individual’s unique clinical, genetic, genomic, and environmental information partly represented by gene expression patterns. An international team of researchers around…

The key objective of this proposal was to further dissect and characterize the cell-specific neuroendocrine signaling mechanisms that underlie the development of obesity, diabetes, and their co-morbidities, with a special emphasis on hypothalamic…

Timo Müller and his team have been working for many years on the development of new therapeutic options for diabetes and obesity. Among other things, they decoded a brain receptor that plays a crucial role in the regulation of body weight and food…

Prof. Cristina García-Cáceres (second left) receives the DAG research award 2022 for her scientific contribution in the field of obesity research. The prize, she shares with Dr. Anne Lautenbach from the University Clinic Hamburg-Eppendorf, was…

A team of researchers from Helmholtz Munich, the German Center for Diabetes Research (DZD) and Novo Nordisk have developed a new hormone combination for the future treatment of type 2 diabetes. The scientists have combined the blood sugar-reducing…

Helmholtz Munich obtains two ERC Consolidator Grants: Timo Müller from the Institute for Diabetes and Obesity with "TRUSTED", and Ben Engel, formerly of the Helmholtz Pioneer Campus, with "cryOcean". They are among the successful 12 percent to…

All News

Diabetes type 2: New biomarkers for patient classification and intervention prediction identified

Matthias Tschöp successfully completed the ERC Project “Targeting Hypothalamic inFlammation in obesity and diabetes (HypoFlam)”

Timo Müller receives the Galenus-von-Pergamon Award 2022

Cristina García-Cáceres receives the DAG research award 2022

New Drug Candidate Developed to Treat Type 2 Diabetes

Two-Pack of Success – Timo Müller and Ben Engel Receive ERC Consolidator Grant